Tirzepatide is one of the best-characterized molecules in modern metabolic medicine. As a dual GIP and GLP-1 receptor agonist, it targets two incretin pathways simultaneously. Its clinical program has generated extensive data on body weight, type 2 diabetes, cardiovascular risk, heart failure and obstructive sleep apnea.
Another important development arrived in 2026. On August 28, 2026, Eli Lilly announced that the U.S. FDA had expanded the indication for Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for these events. This article summarizes major publicly available clinical findings as of September 11, 2026.
What is tirzepatide?
Tirzepatide is a synthetic peptide that acts as a dual agonist of the GIP and GLP-1 receptors. Both receptors are part of the incretin system involved in regulation of glucose, insulin secretion and food intake.
GLP-1 receptor activation is associated with regulation of appetite and energy intake, glucose-dependent insulin secretion and delayed gastric emptying. GIP receptor activation adds a second incretin pathway. This combined GIP + GLP-1 mechanism distinguishes tirzepatide from semaglutide, which primarily targets the GLP-1 receptor.
SURMOUNT-5: direct comparison with semaglutide
The Phase 3b SURMOUNT-5 trial directly compared tirzepatide and semaglutide within the same study. It enrolled 751 adults with obesity but without type 2 diabetes and lasted 72 weeks.
Mean body-weight change was −20.2% with tirzepatide and −13.7% with semaglutide. Mean waist-circumference change was −18.4 cm versus −13.0 cm. In this specific trial, tirzepatide therefore produced a greater average reduction in body weight and waist circumference.
These are results from a controlled clinical trial in a defined population and should not be interpreted as a prediction for an individual.
SURMOUNT-1: long-term data through 176 weeks
The three-year extension of SURMOUNT-1 evaluated participants with obesity or overweight and prediabetes over a 176-week treatment period.
In the highest studied dose group, average body-weight reduction at the end of treatment was 22.9%. When the dose groups were pooled, the risk of progression from prediabetes to type 2 diabetes over 176 weeks was 94% lower than with placebo.
A further 17-week off-treatment follow-up showed some weight regain and some narrowing of the difference in diabetes progression, underscoring the importance of evaluating long-term treatment effects both during and after therapy.
Key studies at a glance
| Study | Population / area | Duration | Main reported result |
|---|---|---|---|
| SURMOUNT-5 | Obesity without type 2 diabetes | 72 weeks | −20.2% body weight vs. −13.7% with semaglutide |
| SURMOUNT-1 | Obesity / overweight + prediabetes | 176 weeks | up to −22.9%; 94% lower risk of progression to type 2 diabetes |
| SURPASS-CVOT | Type 2 diabetes + atherosclerotic CV disease | median 210 weeks | MACE-3 HR 0.92 vs. dulaglutide; noninferiority met |
| SUMMIT | HFpEF + obesity | median follow-up 104 weeks | CV death / worsening heart failure HR 0.62 vs. placebo |
| SURMOUNT-OSA | Moderate-to-severe OSA + obesity | 52 weeks | significant improvement in apnea-hypopnea index; supported U.S. Zepbound approval |
SURPASS-CVOT: cardiovascular outcomes
SURPASS-CVOT is the largest and longest tirzepatide trial completed to date. It enrolled more than 13,000 participants with type 2 diabetes and atherosclerotic cardiovascular disease and compared tirzepatide with dulaglutide, a GLP-1 receptor agonist with established cardiovascular benefit.
The primary MACE-3 endpoint included cardiovascular death, nonfatal myocardial infarction or nonfatal stroke. An event occurred in 12.2% of participants assigned to tirzepatide and 13.1% assigned to dulaglutide. The hazard ratio was 0.92 (95.3% CI, 0.83–1.01).
The trial met the prespecified criterion for noninferiority. Statistical superiority over dulaglutide for the primary endpoint was not established.
2026 update: expanded U.S. indication for Mounjaro
On August 28, 2026, Lilly announced that the FDA approved Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events – cardiovascular death, nonfatal myocardial infarction or nonfatal stroke – in adults with type 2 diabetes who are at high risk for these events.
This indication applies to a specific approved pharmaceutical product and cannot automatically be extended to other materials or products labeled as tirzepatide.
SUMMIT: heart failure and obesity
The SUMMIT trial included 731 people with obesity and heart failure with preserved ejection fraction (HFpEF). Cardiovascular death or a worsening heart-failure event occurred in 9.9% of participants receiving tirzepatide and 15.3% receiving placebo, corresponding to a hazard ratio of 0.62.
The difference was driven mainly by fewer worsening heart-failure events. Tirzepatide also improved the KCCQ-CSS measure of heart-failure symptoms and health status.
Obstructive sleep apnea
In December 2024, Zepbound (tirzepatide) became the first medication approved by the U.S. FDA for moderate-to-severe obstructive sleep apnea in adults with obesity, in combination with a reduced-calorie diet and increased physical activity.
The approval was based on SURMOUNT-OSA trials that demonstrated significant reductions in the apnea-hypopnea index over 52 weeks compared with placebo.
Safety and tolerability
The most commonly reported adverse effects of tirzepatide in clinical trials have been gastrointestinal, including nausea, diarrhea, vomiting, constipation, decreased appetite, dyspepsia and abdominal pain. In SURMOUNT-5, gastrointestinal events were generally mild to moderate and occurred mainly during dose escalation.
Official prescribing information for approved medicines also contains important warnings, contraindications and interaction information. The safety profile therefore cannot be reduced to common gastrointestinal symptoms alone.
Tirzepatide versus semaglutide: what can we actually conclude?
SURMOUNT-5 provides a true head-to-head comparison. In that population, tirzepatide produced a greater average reduction in body weight than semaglutide.
This does not mean that one molecule is automatically the best choice for every patient. Clinical decisions depend on the indication, comorbidities, contraindications, tolerability, access and other individual factors.
An active ingredient is not the same as every product labeled “tirzepatide”
Mounjaro and Zepbound are approved pharmaceutical products with defined manufacturing processes, quality control, excipients, approved indications and official safety information.
Results from clinical trials of these approved medicines cannot automatically be extrapolated to other products labeled as tirzepatide, particularly materials intended only for laboratory or research use.
What does the current research landscape show?
Tirzepatide can no longer be viewed only through the lens of body-weight change. Its clinical program spans type 2 diabetes, long-term diabetes prevention in a selected high-risk population, cardiovascular outcomes, heart failure, sleep apnea and other metabolic complications.
In 2026, tirzepatide is one of the best clinically characterized incretin-based molecules. Interpreting the evidence still requires a clear distinction between the active ingredient, a specific approved medicine and a research material.
Summary
- Tirzepatide activates the GIP and GLP-1 receptors.
- In SURMOUNT-5, average body-weight change was −20.2% with tirzepatide vs. −13.7% with semaglutide at 72 weeks.
- In the 176-week SURMOUNT-1 extension, the highest studied group had an average change of −22.9%, while pooled tirzepatide groups had a 94% lower risk of progression from prediabetes to type 2 diabetes than placebo.
- SURPASS-CVOT demonstrated noninferiority to dulaglutide for MACE-3.
- In August 2026, the FDA expanded Mounjaro's U.S. indication to reduce cardiovascular risk in selected adults with type 2 diabetes.
- Clinical outcomes from approved medicines cannot automatically be extrapolated to research materials.
Information current to September 11, 2026. This article is for educational and informational purposes. It is not medical advice, a guide to use, a dosing recommendation or a treatment recommendation.
